Table of Contents
Overview
Definition of Bioanalysis
Bioanalysis is a specialized sub-discipline of analytical chemistry that focuses on the quantitative measurement of both xenobiotics—such as drugs and their metabolites—and biotics, which include macromolecules like proteins, DNA, and large molecule drugs, within biological systems. This field encompasses the identification and evaluation of substances of interest in various biological matrices, including blood, plasma, serum, urine, and tissue extracts.[5.1] The complexity of bioanalysis arises from the diverse environments it explores, where analytes are often present in low concentrations and may be accompanied by multiple interfering substances. This necessitates sophisticated measurement techniques to ensure accurate results.[1.1] Bioanalysis plays a crucial role in drug discovery and development, as it is essential for determining the concentrations of drugs and their metabolites, as well as various pharmacodynamic biomarkers in biological fluids.[4.1] Historically, the evolution of bioanalytical methodologies has been driven by advancements in pharmacology and pharmacokinetics, highlighting the importance of this field in understanding drug behavior within biological systems.[6.1] Furthermore, bioanalytical method validation is a critical component of regulatory compliance, ensuring that the analytical methods employed are accurate, precise, sensitive, specific, and reliable.[46.1] This validation process is fundamental to the integrity of data generated during drug development, as it confirms that methods consistently deliver results within established acceptance criteria.[47.1]Importance in Pharmaceutical Industry
Bioanalysis is essential in the pharmaceutical industry, particularly in the development and evaluation of new drugs. A key function of bioanalysis is the assessment of pharmacodynamic (PD) biomarkers, which are crucial for establishing proof-of-concept, assisting in dose selection, and measuring responses to medical products or environmental agents. These biomarkers can also serve as secondary endpoints in clinical trials and may be included in product labeling.[8.1] Unlike pharmacokinetic (PK) biomarkers, which track the drug's journey through the body, PD biomarkers evaluate the drug's biological impact, providing insights into its activity and efficacy, such as receptor occupancy or enzyme inhibition.[10.1] Incorporating PD biomarker assays into clinical programs can confirm target engagement, thereby enhancing the likelihood of advancing to later trial phases, particularly Phase III, if clinical efficacy is demonstrated during earlier trials.[7.1] Recent advancements in bioanalytical techniques, particularly mass spectrometry (MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS), have significantly improved the sensitivity, specificity, and throughput of drug analysis. These techniques enable accurate measurement of drug concentrations, determination of pharmacokinetics, and monitoring of drug metabolism, which are vital for ensuring drug safety, efficacy, and regulatory compliance.[14.1] The integration of high-resolution mass spectrometry and innovative trapping techniques has further enhanced the qualitative and quantitative analysis of pharmaceutically relevant molecules, allowing for more efficient drug development processes.[15.1] The application of LC-MS/MS has gained significant attention in recent years as a complementary technique to traditional ligand binding assays, particularly for the absolute quantitation of therapeutic proteins in biological matrices.[18.1] This advancement is crucial for therapeutic monitoring and optimizing drug therapy, especially in the context of personalized medicine, where there is a growing interest in the development and clinical implementation of molecular biomarkers that serve as direct or surrogate indicators of pharmacological effects.[9.1] Furthermore, the multiple reaction monitoring (MRM) technique in LC-MS/MS is capable of differentiating ions from molecules with the same molecular weight; however, it can also reduce the intensity of precursor ions by generating various product ions. The enhancement of specificity through MRM typically involves selecting one product ion for analysis, which may further decrease the detection intensity of analyte ions.[19.1]History
Early Developments in Bioanalysis
The history of bioanalysis is rooted in the foundational concepts of pharmacology and pharmacokinetics, which have significantly influenced the development of bioanalytical methodologies.[6.1] Bioanalysis is defined as the quantification of drugs, their metabolites, or endogenous molecules within biological matrices, which are materials derived from living organisms, such as blood, tissue, sweat, or breast milk.[50.1] The scientific need for accurate bioanalytical techniques emerged from the evolution of pharmacological science, highlighting the importance of reliable analytical systems in this field.[6.1] One of the pivotal advancements in this field was the introduction of rigorous analytical systems, which began with the construction and testing of the analytical ultracentrifuge by Theodor Svedberg and the development of moving-boundary electrophoresis by Arne Tiselius. These innovations laid the groundwork for modern bioanalytical techniques, enabling researchers to analyze biological samples with greater precision and accuracy.[52.1]Milestones in Bioanalytical Techniques
The development of bioanalytical techniques has evolved significantly alongside advancements in pharmacokinetics, with key milestones marking this progression. This journey began in the 1950s with the introduction of radiotracing measurements, which utilized isotopes such as 14C and 3H. Although these early methods were highly sensitive, they lacked the specificity necessary for broader applications in drug development. As the field advanced, more specific techniques emerged, including gas chromatography and high-pressure liquid chromatography, which enhanced the quantitative identification of medications and their metabolites in biological fluids. Bioanalysis, defined as the quantitative identification of these substances, is applied early in the medication development phase to support programs investigating the pharmacokinetics and metabolic processes of chemicals in living cells and animals.[57.1] As the pharmaceutical industry evolved, the demand for more reliable and efficient bioanalytical methods became increasingly evident. This evolution led to the adoption of liquid chromatography-tandem mass spectrometry (LC-MS/MS), which has established itself as the preferred method for the rapid and sensitive quantitation of small molecules, peptides, and proteins in complex matrices such as plasma, blood, urine, feces, and tissue.[67.1] LC-MS/MS revolutionized the field of bioanalysis by providing enhanced precision, sensitivity, and specificity compared to traditional methods like enzyme-linked immunosorbent assays (ELISA).[64.1] The implementation of multiple reaction monitoring (MRM) within LC-MS/MS further improved specificity by enabling the differentiation of ions from molecules with the same molecular weight; however, this technique can reduce the intensity of precursor ions by generating various product ions, which may pose challenges in detection.[66.1] The advancements in bioanalytical techniques have not only improved the accuracy of drug quantification but have also streamlined workflows in drug development. Automated systems and enhanced sensitivity have contributed to faster data acquisition and analysis, thereby reducing costs and shortening development timelines.[54.1] Furthermore, bioanalytical methods have become integral at every stage of drug development, from lead optimization to clinical trials, guiding critical decision-making processes.[59.1] In recent years, the regulatory landscape has also evolved, with agencies implementing guidelines such as ICH M10 to standardize bioanalytical method validation. However, challenges remain in harmonizing interpretations of these guidelines across different testing facilities.[63.1] Overall, the milestones in bioanalytical techniques reflect a continuous effort to enhance the reliability and efficiency of drug development processes, ensuring that bioanalysis remains a vital component of modern pharmaceutical research.In this section:
Recent Advancements
Modern Techniques in Bioanalysis
Recent advancements in bioanalysis have significantly transformed the field, particularly through the integration of modern techniques such as microsampling, nanotechnology, and the application of artificial intelligence (AI) and machine learning (ML). Modern bioanalysis is undergoing significant transformation due to advancements in microsampling technologies, which include microfluidic systems, quantitative dried blood spot systems (qDBS), and volumetric absorptive microsampling (VAMS).[108.1] These innovative methods are designed to address the challenges associated with traditional sample collection techniques, such as venipuncture, which can lead to patient discomfort, logistical complexities, and increased costs, especially in decentralized or resource-limited environments.[108.1] The latest developments in microsampling devices also encompass calibrated capillary-based devices, microneedle-based microsampling, and membrane-based plasma separation technologies, all of which are tailored to meet specific analytical needs.[108.1] By facilitating the collection of smaller sample volumes while maintaining the integrity of the analysis, these techniques enhance the accuracy of bioanalytical methods.[108.1] Overall, the integration of these modern microsampling approaches is poised to improve patient outcomes through less invasive sample collection methods, thereby revolutionizing the field of bioanalysis.[108.1] Recent advancements in nanotechnology have significantly enhanced bioanalytical methods, particularly through the miniaturization of systems and the integration of various components such as sensors, fluidics, and signal-processing circuits. This integration allows for the large-scale combination of biochemical reactions on a smaller footprint, thereby improving the sensitivity and throughput of biosensors.[94.1] Nanomaterials, which possess superior properties including a large surface area, small size, and great stability, have been pivotal in this evolution, enabling versatile modifications of material surfaces.[95.1] Furthermore, numerous nanophotonic biosensors have been developed to address the limitations of existing bioanalytical methods, particularly in terms of sensitivity, ease of use, and miniaturization.[96.1] The incorporation of DNA nanotechnology into these processes has also played a crucial role in advancing both bioanalysis and clinical diagnostics.[97.1] The integration of Artificial Intelligence (AI) and Machine Learning (ML) technologies is driving a transformative shift in the pharmaceutical industry, particularly in the design, testing, and regulatory processes of drug development.[102.1] These technologies are essential for addressing the bioanalytical challenges that have emerged with the increasing discovery and development of biotherapeutics, including novel modalities such as bioconjugates.[100.1] The inherent complexity of these conjugated molecular structures necessitates sophisticated bioanalytical methods and comprehensive strategies to ensure successful drug discovery and development.[99.1] By leveraging past experiences and knowledge from both small and large molecules, AI and ML can guide the development of effective bioanalytical strategies tailored to these new therapeutic approaches.[99.1]Regulatory Changes and Guidance
Recent advancements in bioanalytical methods have prompted significant regulatory changes and the introduction of new guidance documents aimed at ensuring the reliability and accuracy of drug development processes. In May 2022, the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) adopted Guideline M10, which provides comprehensive recommendations for the validation of bioanalytical methods and the analysis of study samples. This guideline emphasizes the necessity for cross-validation when different laboratories or methods are employed to support the same study, as well as when utilizing different bioanalytical approaches, such as ligand binding and liquid chromatography-tandem mass spectrometry (LC–MS/MS).[106.1] The World Health Organization (WHO) has published a draft working document entitled "Bioanalytical Method Validation and Study Sample Analysis" (QAS/23.925).[103.1] This guideline is intended to provide recommendations for the validation of bioanalytical methods used in the quantification of chemical and biological drugs, as well as their application in the analysis of study samples.[103.1] It is critical that the bioanalytical methods employed are well characterized, appropriately validated, and thoroughly documented to ensure reliable data that supports regulatory decisions.[104.1] Moreover, the validation of bioanalytical methods is recognized as a critical component of effective drug discovery and development. Successful validation ensures that methods consistently deliver accurate and precise results within the required acceptance criteria and timelines. Laboratories experienced in method transfer can significantly reduce drug development timelines when transitioning to new species.[105.1] Despite these advancements, challenges remain in the compliance landscape. Variations in the interpretation of ICH M10 guidelines among bioanalytical testing facilities can lead to inconsistencies in method validation and application.[123.1] As regulatory standards continue to evolve, it is essential for companies to adopt strategies that navigate these changes effectively, ensuring high-quality data generation in bioequivalence laboratories and addressing new regulatory challenges associated with novel modalities.[122.1] The 18th Workshop on Recent Issues in Bioanalysis (18th WRIB) was held in San Antonio, TX, USA, from May 6-10, 2024, and attracted over 1,100 professionals from pharmaceutical and biotechnology companies, contract research organizations (CROs), and various regulatory agencies to engage in discussions on the latest topics in bioanalysis.[125.1] The workshop highlighted the importance of understanding evolving regulatory standards, particularly concerning the impact of Laboratory Developed Tests (LDT) in the United States and the In Vitro Diagnostic Regulation (IVDR) in the European Union.[125.1] As these regulatory frameworks continue to develop, it is essential for industry professionals to stay informed and adapt their strategies to ensure compliance and effectively navigate the complexities of bioanalytical methods.[125.1]In this section:
Types Of Bioanalytical Methods
Small Molecule Analysis
Small molecule analysis in bioanalysis is centered on the precise quantification of pharmacological compounds, drug products, and biological materials. Techniques such as liquid chromatography coupled with mass spectrometry (LC-MS) are pivotal for accurately detecting drugs and their metabolites in biological matrices like serum, plasma, and urine.[142.1] The focus here is on the technical aspects and validation of these methods, ensuring they meet the necessary standards for accuracy and reliability. The sensitivity of these methods is a key factor, defined by the lower limit of quantification (LLOQ), which represents the smallest concentration of an analyte that can be measured with consistent accuracy and precision.[143.1] LC-MS methods, for example, can achieve LLOQs as low as 0.1 ng/mL, though this can vary depending on the method, with some having higher LLOQs like 2.0 ng/mL.[144.1] This variability is crucial for selecting the appropriate method based on specific analytical needs. Specificity is another critical parameter, with LC-MS methods offering high specificity necessary for the accurate identification and quantification of analytes in complex matrices.[144.1] The robustness of these methods, which refers to their ability to remain stable despite minor variations in parameters, enhances their reliability in routine applications.[161.1] Validation of bioanalytical methods is a structured process that ensures the accuracy and reliability of results. This involves assessing accuracy and precision through multiple determinations at various concentration levels, with at least five determinations per level recommended.[160.1] Developing and implementing standard operating procedures (SOPs) for method validation is essential to meet regulatory standards and support high-quality data generation.[159.1]Macromolecule Analysis
Bioanalytical methods are essential procedures for collecting, processing, storing, and analyzing biological matrices to detect chemical compounds. This quantitative analysis, known as bioanalysis, is vital in the early stages of drug development, providing crucial insights into the metabolic fate and pharmacokinetics of compounds within living cells, thereby aiding drug discovery programs.[132.1] The validation of these methods, referred to as Bioanalytical Method Validation (BMV), ensures that the analytical techniques used are appropriate for biochemical applications.[131.1] BMV is critical for confirming that quantitative analytical methods are suitable for biochemical applications. These methods are indispensable in drug discovery, development, and therapeutic monitoring, ensuring the precise quantification of drugs, metabolites, and biomarkers in biological matrices such as plasma, serum, or urine.[134.1] In clinical and Good Laboratory Practice (GLP) nonclinical studies, these methods must comply with regulatory requirements and guidance for both prestudy and in-study validations to support regulatory submissions.[135.1]Applications Of Bioanalysis
Drug Development and Pharmacokinetics
Bioanalysis plays a crucial role in drug development and pharmacokinetics by enabling the quantitative measurement of drugs, their metabolites, and various pharmacodynamic biomarkers in biological fluids. This sub-discipline of analytical chemistry is essential for determining the concentration of these substances, which is vital for assessing drug efficacy and safety during the development process.[172.1] The integration of bioanalytical techniques, particularly liquid chromatography coupled with tandem mass spectrometry (LC-MS-MS), has become essential for successful drug development. These techniques are critical for structural characterization, quality control, and bioanalytical studies, which must be as accurate, sensitive, and selective as possible.[181.1] For the past 30 years, LC-MS-MS has been the technique of choice for many areas of small molecule analysis, demonstrating high capability in identifying the molecular weight and structure of biomolecules with remarkable accuracy and sensitivity.[181.1] Recent advances in mass spectrometry have further enhanced its role in drug discovery and development, significantly improving the efficiency and accuracy of these processes.[173.1] By combining high-performance chromatography with mass spectrometry, bioanalytical techniques have achieved unprecedented levels of sensitivity, precision, and reliability, thereby providing essential tools for pharmaceutical research and clinical testing.[176.1] On January 21, 2025, the U.S. Food and Drug Administration (FDA) issued final guidance titled "Bioanalytical Method Validation for Biomarkers," emphasizing the significance of robust bioanalytical methods in the evaluation of biomarkers during drug development.[178.1] This guidance aims to clarify the validation processes for bioanalytical methods used to measure biomarkers in biological matrices, such as blood and urine, and highlights that biomarker assays often necessitate a fit-for-purpose validation approach tailored to their intended use in regulatory decision-making or internal pharmaceutical development.[178.1] Furthermore, the guidance outlines recommendations for method validation of bioanalytical assays utilized in nonclinical and clinical studies, detailing the necessary procedures and processes for chromatographic and ligand-binding assays that measure the parent and active metabolites of drugs administered to subjects.[180.1] These recommendations are crucial for generating data that supports regulatory submissions, ensuring that the methods employed meet the required standards for drug approval.[180.1] In addition to traditional methods, innovative techniques such as imaging mass spectrometry are emerging as valuable tools in drug discovery, facilitating better decision-making by providing detailed molecular information.[175.1] The incorporation of these advanced bioanalytical methods into various stages of drug development underscores their pivotal role in ensuring the safety, efficacy, and regulatory compliance of pharmaceutical products.[174.1]Challenges In Bioanalysis
Method Validation Issues
Method validation is a critical component of bioanalytical method development, as it is essential for ensuring regulatory compliance. The International Council for Harmonisation (ICH) and the U.S. Food and Drug Administration (FDA) have established comprehensive guidelines that outline the requirements for method validation in this field.[214.1] One of the most common challenges faced by bioanalytical laboratories is related to reporting issues, which can include deficiencies in data quality, sample receipt, sample preparation procedures, or missing information. Such reports cannot be accepted by regulatory authorities if they contain these issues.[214.1] Therefore, meticulous documentation and adherence to good practices are fundamental to achieving compliance. A comprehensive approach that emphasizes detailed record-keeping, compliance with established guidelines, and careful attention to technical details is crucial for maintaining data integrity and meeting regulatory standards in bioanalytical method development.[214.1] Historically, the lack of uniformity in method validation procedures and acceptance criteria has posed significant challenges within the bioanalytical community. For many years, these procedures were subject to personal biases, resulting in inconsistencies that complicated the validation process.[215.1] Recent observations from the FDA indicate that a high percentage of 483 observations issued to bioanalytical laboratories are linked to method validation issues, underscoring the need for stringent adherence to validation guidelines.[216.1] To address these challenges, regulatory bodies such as the International Council for Harmonisation (ICH) and the FDA have established comprehensive guidelines for method validation. These guidelines stress the necessity of thorough documentation and record-keeping as fundamental components of regulatory compliance in bioanalytical method development.[214.1] By integrating these practices, laboratories can enhance the reliability of their methods and ensure that they meet the rigorous standards required for regulatory approval.Technological Limitations
Bioanalysis faces significant technological limitations, particularly when it comes to analyzing complex biological matrices such as plasma, serum, and whole blood. One of the primary challenges is the need to accurately determine pharmaceutically active compounds at very low concentrations amidst a backdrop of endogenous compounds that can interfere with the detection of target therapeutic proteins. This necessitates the removal of these interfering substances as much as possible to ensure data quality and reliability.[247.1] The complexity of biological samples introduces additional hurdles during the sample preparation phase, which is critical for achieving accurate results. These samples often contain moderate to high levels of proteins, and variability can arise not only between different individuals (inter-personal variability) but also within the same individual over time (intra-personal variability).[249.1] Such variability can complicate the reproducibility of bioanalytical methods and affect the overall quality of the data generated. Moreover, the analytical techniques employed, such as liquid chromatography-mass spectrometry (LC-MS), can be adversely affected by minor changes in mobile phase composition or gradient programs, leading to coelution of matrix components and ion suppression. While hydrophilic interaction liquid chromatography (HILIC) is anticipated to provide greater sensitivity compared to reversed-phase liquid chromatography (RPLC), some studies have reported higher limits of quantification (LOQs) with HILIC methods, indicating that the choice of analytical technique can significantly impact the outcomes of bioanalytical assays.[248.1] To address these challenges, innovative methodologies are being explored. The integration of microfluidics with advanced technologies, such as nanotechnology and deep learning, presents new opportunities for enhancing bioanalytical processes. For instance, nanoliter-scale electro-membrane extraction within microfluidic devices has been successfully employed to extract model analytes from small volumes of blood, plasma, or urine, thereby improving the efficiency and sensitivity of the analysis.[251.1] These advancements highlight the ongoing efforts to overcome the technological limitations inherent in bioanalysis, paving the way for more reliable and accurate assessments of drug compounds in complex biological environments.In this section:
Future Directions
Innovations in Bioanalytical Techniques
Recent advancements in bioanalytical techniques have significantly transformed the landscape of biomolecule analysis, focusing on innovative methods and technologies. A special issue titled "Recent Advances in Bioanalysis," set to be published in the Journal of Chromatography Open, aims to highlight these developments, particularly in separation technologies, detection techniques, and process modeling for bioanalytical development.[252.1] Emerging technologies such as microfabrication, advanced materials, and electronics have driven trends in bioanalysis, enabling the creation of smaller, more portable, and cost-effective bioanalytical devices.[253.1] Notably, recent reviews have summarized advancements in sample preparation techniques, including novel methods like electromembrane extraction and microfluidic devices, which enhance the quantitative analysis of pharmaceuticals.[254.1] Innovations in microsampling devices have also gained attention, with advancements in microfluidic systems and quantitative dried blood spot (DBS) technologies. These include volumetric absorptive microsampling (VAMS) and microneedle-based systems, which improve patient comfort and analytical efficiency by allowing for minimally invasive fluid collection.[255.1] Furthermore, the emphasis on green sample preparation (GSP) has led to the development of novel sorbent materials and microextraction techniques, which are crucial for sustainable bioanalytical practices.[256.1] The integration of microfluidic chips with analytical techniques presents additional benefits, such as miniaturization and reduced biological sample volume requirements, which are essential for point-of-care (POC) diagnostics.[258.1] Additionally, the application of microelectromechanical systems (MEMS) has facilitated the incorporation of nano-biosensors into microfluidic devices, enhancing the precision and versatility of bioanalytical tools.[259.1] The integration of artificial intelligence (AI) and machine learning (ML) into bioanalytical techniques is transforming the field significantly. Recent advances in data-analysis techniques, particularly those involving ML, demonstrate the potential to extract latent beneficial information from complex bioanalytical data, thereby facilitating the exploration of unknown relationships and patterns.[261.1] AI systems that utilize deep neural networks and ML algorithms are increasingly employed to address critical challenges in bioinformatics, biomedical informatics, and precision medicine.[262.1] While the automation of bioanalytical processes through AI is anticipated, the primary application of these technologies currently focuses on enhancing data analysis capabilities.[266.1] As the field evolves, the role of AI in automating sample preparation techniques is expected to grow, although solid-phase extraction remains one of the most frequently used methods in bioanalysis at present.[266.1]In this section:
References
[1] Bioanalysis - an overview | ScienceDirect Topics — Summary. Bioanalysis is complex due to the wide range of environments that can be explored. There are significant challenges in measurement due to the nature of analytes being present in small concentrations in distinct locations where often multiple other interfering substances are present. Additionally, the timescale that the analytes of
[4] Bioanalysis, Bioanalytics, Bioanalytical Assays - NorthEast BioLab — Bioanalysis is an essential tool in drug discovery and development for determining the concentration of drugs and their metabolites as well as various pharmacodynamics biomarkers in biological fluids. In these analyses, scientists use developed and validated methods to quantitatively detect analytes and metabolites within biological matrices such as serum, plasma, urine,
[5] PDF — Bioanalysis is a sub-discipline of analytical chemistry and by and large includes the distinguishing proof and evaluation of a substance of interest (generally xenobiotics or biotics) in a given organic example, for instance blood, plasma, serum, pee or tissue extricates. Bioanalytics is a fundamental
[6] Regulated Bioanalysis—Historical Aspects and Key Concepts ... - Springer — The history and key concepts of bioanalysis are discussed. Historically, the scientific need driving the development of bioanalytical methodology was the evolution of the science of pharmacology as well as the field of pharmacokinetics.
[7] Pharmacodynamic (PD) Biomarkers | Charles River — If you're unable to prove clinical efficacy during Phase I or II clinical trials, your program may fail. Incorporating proof of mechanism endpoints into your program means pharmacodynamic (PD) biomarker assays can confirm target engagement, improving your chances of moving to Phase III. Charles River can customize PD biomarker assays to support go/no-go decisions for your program.
[8] Response Biomarker - BEST (Biomarkers, EndpointS, and other Tools ... — Potential uses of a pharmacodynamic biomarker include establishing proof-of- concept, assisting in dose selection or measuring a response to medical products or environmental agents, including the use as a measure of potential harm. In some cases, such measures may be secondary endpoints in clinical trials and may be described in labeling.
[9] Improving therapeutic decisions: Pharmacodynamic monitoring as an ... — Therefore, during recent years there is an increased interest in personalized drug therapy as reflected by the development and clinical implementation of molecular "biomarkers" that are direct or surrogate markers of pharmacological effects (pharmacodynamic therapeutic drug monitoring, PD TDM).
[10] An Introduction to the Use of Pharmacodynamic Biomarkers in Drug ... — Unlike pharmacokinetic (PK) biomarkers, which measure the drug's journey through the body, pharmacodynamic biomarkers assess the drug's biological impact. They can be indicators of a drug's activity and efficacy, such as receptor occupancy or enzyme inhibition, providing invaluable insight into the drug's mechanism of action.
[14] PDF — The use of mass spectrometry in the pharmaceutical industry enables accurate measurement of drug concentrations, determination of pharmacokinetics, and monitoring of drug metabolism. These capabilities are essential for ensuring drug safety, efficacy, and regulatory compliance.
[15] Mass spectrometry based approaches and strategies in bioanalysis for ... — The present review summarizes some the most common applications of LC-MS for the characterization of therapeutic low-molecular-weight compounds, peptides and proteins, and oligonucleotides using low-resolution and high-resolution tandem mass spectrometry. Moreover, bioanalysis has since then been taking advantage of instrumental developments, for example those related to liquid chromatography, high-resolution mass spectrometry (HRMS), ion mobility spectrometry, and innovative trapping techniques which all proved to be valuable techniques in the qualitative and quantitative analysis of pharmaceutically relevant molecules. Besides aiding in the structural elucidation of drug metabolites, this additional dimension of separation may even allow for shortening analysis times, as was recently shown for a quantitative method based on hyphenated differential mobility spectrometry (DMS-) mass spectrometric detection .
[18] Strategies for improving sensitivity and selectivity for the ... — In recent years, the applicability of using LC-MS/MS as a complementary technique to traditional ligand binding assays in the absolute quantitation of therapeutic proteins in biologic matrix has been demonstrated. Protein quantitation workflow via LC-MS/MS is primarily based on a enzymatic digestion …
[19] Enhancement of Sensitivity and Quantification Quality in the LC-MS/MS ... — The MRM technique in LC-MS/MS can differentiate ions from molecules with same molecular weight but reduces the intensity of precursor ions by producing various product ions. Using MRM in LC-MS/MS to enhance specificity usually relies on selecting one product ion for analysis, which further decreases the detection intensity of analyte ions.
[46] Ensuring Regulatory Compliance in Bioanalytical Method Development — At the core of regulatory compliance lies bioanalytical method validation. This critical process demonstrates that the analytical methods used to measure drug concentrations and biomarkers in biological samples are accurate, precise, sensitive, specific, and reliable.
[47] Bioanalytical method revalidation challenges in pharma R&D — Bioanalytical method validation is the backbone of effective drug discovery and development. Whether method developers and sponsors do this work in-house or call on a laboratory partner for help, successful validation is when the method consistently delivers accurate and precise results within the required acceptance criteria and timeline. Laboratories with experience in method transfer can help shorten drug development timelines when transitioning to a new species. Beyond these, Dr. Lai has earned extensive experience in GLP/GCP/GCLP regulated preclinical/clinical bioanalysis of large molecule pharmacokinetics (PK), immunogenicity and PD biomarkers for various drug modalities, from method development, validation to study sample analysis. Tagged With: Bioanalytical method validation, drug discovery, pharmaceutical development, Regulatory Compliance, species-specific challenges
[50] History of Bioanalysis | Bioanalysis 101 — History of Bioanalysis To understand the history of bioanalysis it is important to define what bioanalysis. Bioanalysis is the quantification of a drug, a metabolite of the drug, or a endogenous molecule within a biological matrix. A biological matrix is simply material derived from a living organism such as blood, tissue, sweat, or breast milk.
[52] Bioanalysis: its past, present, and some future - PubMed — An overview of about 100 years of bioanalysis is here disastrously attempted. The beginning of rigorous analytical systems can perhaps be traced back to the building and testing of the analytical ultracentrifuge by Svedberg and the apparatus for moving-boundary electrophoresis of Tiselius, both syst …
[54] PDF — procedures further improve reliability. As the pharmaceutical industry advances, adopting cutting-edge bioanalytical techniques and automation will streamline workflows and deliver accurate, reproducible data, accelerating drug development and ensuring product quality . References: Eag Laboratories. (N.D.).
[57] Development steps of pharmacokinetics: a perspective on bioanalytical ... — This paper describes the main development steps of pharmacokinetics that paralleled the development of analytical bioassay methods. From the first stirrings on 1950s, with very sensitive but not specific radiotracing measurements using 14C or 3H labelled drugs, to further developments with more specific methods like gas chromatography, high pressure liquid chromatography, to the last
[59] Bioanalysis in drug discovery and development - PMC — The emergence of the field of bioanalysis as a critical tool during the process of drug discovery and development is well understood and globally accepted.[6–9] Over the past few decades, a plethora of assays has been continuously developed for NCEs to support various stages of discovery and development, including assays for important metabolites.[10–14] Additionally, multiple analytical procedures are available for prescription medicines (Rx) and/or generic products.[15–23] Bioanalytical data generated in discovery and pre-clinical programs are a valuable guide to early clinical programs. Since the complexity of development generally tends to increase as the lead candidate enters the toxicological and clinical phase of testing, it naturally calls for improved methods of analytical quantization, improvement in selectivity and specificity, and employment of sound and rugged validation tools to enable estimation of PK parameters that would also aid in the decision-making of the drug molecule's advancement in the clinic in addition to safety and tolerability data gathered at all phases of development.
[63] PDF — Q&A: Harmonizing Bioanalytical Method Validation – Navigating the Complex Landscape of Global Regulatory Standards w o r l d w i d e . c o m | p g 2 White Paper | Q&A: Harmonizing Bioanalytical Method Validation – Navigating the Complex Landscape of Global Regulatory Standards Despite ICH M10’s efforts to clarify and standardize the entire process from assay development to sample testing, variations in interpretation persist among bioanalytical testing facilities. c o m | p g 3 White Paper | Q&A: Harmonizing Bioanalytical Method Validation – Navigating the Complex Landscape of Global Regulatory Standards c o m | p g 4 White Paper | Q&A: Harmonizing Bioanalytical Method Validation – Navigating the Complex Landscape of Global Regulatory Standards M10 guidance: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m10-bioanalytical-method-validation-and-study-sample-analysis 3.
[64] The advantages and the limitations of LC-MS/MS and Elisa methods in ... — LC-MS/MS: Precision, sensitivity, and specificity in biomolecular analysis. While ELISA has long served as a mainstay in biomolecular analysis, LC-MS/MS has emerged as a gold standard, revolutionizing the field with its precision, sensitivity, and specificity.This method uses a combination of liquid chromatography and tandem mass spectrometry to provide a comprehensive approach to identifying
[66] Enhancement of Sensitivity and Quantification Quality in the LC-MS/MS ... — The MRM technique in LC-MS/MS can differentiate ions from molecules with same molecular weight but reduces the intensity of precursor ions by producing various product ions. Using MRM in LC-MS/MS to enhance specificity usually relies on selecting one product ion for analysis, which further decreases the detection intensity of analyte ions.
[67] Mass Spectrometry In Bioanalysis: Liquid Chromatography-Tandem Mass ... — Liquid chromatography-tandem mass spectrometry (LC/MS/MS) is the preferred method for the fast and sensitive quantitation of small molecules, peptides, and proteins in complex matrices including plasma, blood, urine, feces, and tissue 1.For most compounds, a mass spectrometer is more sensitive and significantly more specific than other LC detectors such as UV-Vis, fluorescence, and
[94] Current nanotechnology advances in diagnostic biosensors — Nanotechnology allows the next level of miniaturization of bioanalytical systems, by integrating sensors, fluidics and signal-processing circuits, which can provide the large-scale integration of different biochemical reactions on a smaller footprint (Vashist et al., 2012; Zhang et al., 2009), contributing for biosensors to achieve current
[95] Advancement in bioanalytical science through nanotechnology: Past ... — The latest developments in design and synthesis of nanomaterials resulted in many applications in bioanalytical sciences , .Nanomaterials exhibit superior properties such as large surface area, very small size, great stability, and versatile chemistry for the modification of the material surface .The physicochemical features of these materials in the range between 1 and 100 nm are
[96] Advances and applications of nanophotonic biosensors — Numerous nanophotonic biosensors have emerged to address the limitations of the current bioanalytical methods in terms of sensitivity, throughput, ease-of-use and miniaturization.
[97] DNA‑Directed Assembly of Photonic Nanomaterials for Diagnostic and ... — [4, 7-11] The integration of DNA nanotechnology into this process has revolutionized the assembly of photonic ... advancing both bioanalysis and clinical diagnosis. SERS probes have also been functionalized with aptamers for in situ tracking of target biological events. Using such a nanoprobe, not only intracellular molecules
[99] PDF — Sophisticated bioanalytical methods and comprehensive strategies are crucial for the success of drug discovery and the development of these emerging therapeutic approaches. Past experience with and knowledge gained from the use of small and large molecules can help guide the bio-analytical strategies and methods development for new
[100] Bioanalytical Methods and Strategic Perspectives Addressing the Rising ... — In recent years, an increase in the discovery and development of biotherapeutics employing new modalities, such as bioconjugates or novel routes of delivery, has created bioanalytical challenges. The inherent complexity of conjugated molecular structures means that quantification of the bioconjugate …
[102] (Pdf) Integration of Artificial Intelligence in The Pharmaceutical ... — The integration of Artificial Intelligence (AI) into the pharmaceutical process represents a transformative shift in how drugs are designed, tested, and brought to market.
[103] WHO Draft Working Document on Bioanalytical Method Validation published ... — The World Health Organization (WHO) has published a draft working document entitled Bioanalytical Method Validation and Study Sample Analysis (QAS/23.925).. Content. The "guideline is intended to provide recommendations for the validation of bioanalytical methods for chemical and biological drug quantification and their application in the analysis of study samples."
[104] ICH M10 on bioanalytical method validation - Scientific guideline — It is therefore critical that the bioanalytical methods used are well characterised, appropriately validated and documented in order to ensure reliable data to support regulatory decisions. ... 21/01/2023. English (EN) (585.7 KB - PDF) First published: 27/07/2022. View. ICH guideline M10 on bioanalytical method validation and study sample
[105] Bioanalytical method revalidation challenges in pharma R&D — Bioanalytical method validation is the backbone of effective drug discovery and development. Whether method developers and sponsors do this work in-house or call on a laboratory partner for help, successful validation is when the method consistently delivers accurate and precise results within the required acceptance criteria and timeline. Laboratories with experience in method transfer can help shorten drug development timelines when transitioning to a new species. Beyond these, Dr. Lai has earned extensive experience in GLP/GCP/GCLP regulated preclinical/clinical bioanalysis of large molecule pharmacokinetics (PK), immunogenicity and PD biomarkers for various drug modalities, from method development, validation to study sample analysis. Tagged With: Bioanalytical method validation, drug discovery, pharmaceutical development, Regulatory Compliance, species-specific challenges
[106] ICH M10 Bioanalytical Method Validation Guideline-1 year Later — In May 2022, the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) adopted Guideline M10, "Bioanalytical Method Validation and Study Sample Analysis." (1) This document provides guidance on validating bioanalytical methods and analyzing study samples. In addition to specifying the need for cross-validation when different laboratories/methods are used to support the same study or when different methods using the same analytical platform are used to support a development program, ICH M10 also calls out the need for cross-validation when two different bioanalytical approaches, for example, ligand binding and liquid chromatography-tandem mass spectrometry (LC–MS/MS), are utilized during a drug development program.
[108] New trends in bioanalysis sampling and pretreatment: How modern ... — This review explores the latest advancements in microsampling devices, including microfluidic and quantitative dried blood spot systems (mfDBS and qDBS, respectively), calibrated capillary-based devices, volumetric absorptive microsampling (VAMS) technologies, microneedle-based microsampling, radial-based DBS devices, membrane-based plasma separation technologies and vacuum-assisted blood collection systems. Modern innovations include volumetric absorptive microsampling (VAMS), advanced DBS platforms (e.g. based on microfluidics and capillary systems), membrane-based plasma separation and minimally invasive fluid capillary blood collection technologies, each tailored to specific applications and analytical needs. Other approaches dispense with a separated skin-prick moment and directly integrate microneedles into the device for better patient comfort, obtaining either fluid microsamples or dried blood samples on polymer (Tasso-M20).
[122] 2024 White Paper on Recent Issues in Bioanalysis: Three Way-Cross ... — Navigating Success: Strategies for high quality data in bioequivalence laboratories. ... 4.1. New Regulatory Challenges in Bioanalysis for Novel Modalities. ... Although some small changes in peptide response and linearity were realized, limits of quantitation and reproducibility were conserved reinforcing the validity of utilizing this
[123] PDF — Q&A: Harmonizing Bioanalytical Method Validation – Navigating the Complex Landscape of Global Regulatory Standards w o r l d w i d e . c o m | p g 2 White Paper | Q&A: Harmonizing Bioanalytical Method Validation – Navigating the Complex Landscape of Global Regulatory Standards Despite ICH M10’s efforts to clarify and standardize the entire process from assay development to sample testing, variations in interpretation persist among bioanalytical testing facilities. c o m | p g 3 White Paper | Q&A: Harmonizing Bioanalytical Method Validation – Navigating the Complex Landscape of Global Regulatory Standards c o m | p g 4 White Paper | Q&A: Harmonizing Bioanalytical Method Validation – Navigating the Complex Landscape of Global Regulatory Standards M10 guidance: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m10-bioanalytical-method-validation-and-study-sample-analysis 3.
[125] Full article: 2024 White Paper on Recent Issues in Bioanalysis ... — 1. Introduction. The 18 th Workshop on Recent Issues in Bioanalysis (18 th WRIB) took place in San Antonio, TX, USA on May 6-10, 2024. Over 1100 professionals representing pharma/biotech companies, CROs, and multiple regulatory agencies convened to actively discuss the most current topics of interest in bioanalysis.
[131] BIOANALYTICAL TECHNIQUES - AN OVERVIEW - PharmaTutor — A bioanalytical method is a set of procedures involved in the collection, processing, storage, and analysis of a biological matrix for a chemical compound. Bioanalytical method validation (BMV) is the process used to establish that a quantitative analytical method is suitable for biochemical applications.
[132] Bioanalytical Methods - An Overview - Bio-Analysis Centre — Bioanalytical Methods - An Overview The quantitative determination of substances and their metabolites in biological fluids is known as bioanalysis. This technique is employed early in the drug development process to aid drug discovery programmes by providing information on the metabolic fate and pharmacokinetics of compounds in living cells
[134] Bioanalytical Method Development and Validation: A Comprehensive Review — Bioanalytical methods play a pivotal role in drug discovery, development, and therapeutic monitoring. These methods ensure accurate quantification of drugs, metabolites, and biomarkers in biological matrices such as plasma, serum, or urine. This review article delves into the critical aspects of bioanalytical method development and validation, including chromatographic techniques, regulatory
[135] Bioanalytical Method - an overview | ScienceDirect Topics — 24.1.3 Bioanalysis of biological matrix samples in drug development. When bioanalytical methods are used for the sample analysis of clinical studies and GLP nonclinical studies for supporting regulatory submissions, there are regulatory requirements and guidance for the prestudy and in-study validations, 1-4 in addition to the other aspects of the study conducts.
[142] Bioanalysis, Bioanalytics, Bioanalytical Assays - NorthEast BioLab — Bioanalysis is an essential tool in drug discovery and development for determining the concentration of drugs and their metabolites as well as various pharmacodynamics biomarkers in biological fluids. In these analyses, scientists use developed and validated methods to quantitatively detect analytes and metabolites within biological matrices such as serum, plasma, urine,
[143] Comparative assessment of bioanalytical method validation guidelines ... — The sensitivity of a bioanalytical method is expressed at the LLOQ, which is defined as the lowest concentration of an analyte at which the analyte can be quantified with reliable accuracy and precision. ... USFDA guidance has not mentioned LBA and later in the new draft guidance LBA method validation was included, still specificity is not
[144] PDF — 4 Cross Validation Results 5 Comparison of Both Methods Property PNA-HPLC-Assay LC-MS/MS-Assay Sensitivity 0.1 ng/mL 2.0 ng/mL Specificity High Highest Metabolite Analysis Yes Yes Metabolite Identification No, only indirect Yes Robustness High Medium Matrix Effects Low Medium Sample Preparation Procedure Simple Complex
[159] Standard Operating Procedure (SOP) for Bioanalytical Method ... - eLeaP — Ensure the accuracy and reliability of your bioanalytical testing with our Standard Operating Procedure (SOP) for Bioanalytical Method Validation. Designed for life sciences organizations, this SOP provides a structured approach to validating bioanalytical methods to ensure they meet regulatory standards and support high-quality data generation.
[160] Bioanalytical method validation: An updated review - PMC — The development of sound bioanalytical method(s) is of paramount importance during the process of drug discovery and development, culminating in a marketing approval. ... For validation of the bioanalytical method, accuracy and precision should be determined using a minimum of five determinations per concentration level (excluding blank samples
[161] Bioanalytical Method Validation: Concepts, Expectations and Challenges ... — In short, robustness of a method is a measure of its capacity to remain unaffected by small but deliberate variations in method parameters and provides an indication of its reliability during normal usage ; while ruggedness is the degree of reproducibility of the test results obtained by the analysis of the same samples under a variety of
[172] Bioanalysis, Bioanalytics, Bioanalytical Assays - NorthEast BioLab — Bioanalysis is an essential tool in drug discovery and development for determining the concentration of drugs and their metabolites as well as various pharmacodynamics biomarkers in biological fluids. In these analyses, scientists use developed and validated methods to quantitatively detect analytes and metabolites within biological matrices such as serum, plasma, urine,
[173] Developments of mass spectrometry-based technologies for effective drug ... — Recent advances in mass spectrometry have been demonstrating its high capability in identifying the molecular weight and structure of a biomolecule/compound in high throughput and with high accuracy and high sensitivity, and MS-based technologies will inevitably play an important role in drug discovery and development, greatly more than ever.
[174] Mass Spectrometry Techniques in Pharmaceutical Analysis: A Pathway to ... — Mass spectrometry's incorporation into diverse stages of drug development and manufacturing highlights its pivotal role in shaping pharmaceutical analysis. Its contribution to ensuring the safety, efficacy, and regulatory adherence of pharmaceutical products is firmly established and continues to adapt with technological advancements.
[175] The emergence of imaging mass spectrometry in drug discovery and ... — The emergence of imaging mass spectrometry in drug discovery and development: Making a difference by driving decision making J Mass Spectrom . 2021 Aug;56(8):e4717. doi: 10.1002/jms.4717.
[176] PDF — complex biological samples. By combining high-performance chromatography with mass spectrometry, bioanalytical techniques have reached new levels of sensitivity, precision, and reliability, providing an essential tool for pharmaceutical research and clinical testing. Advancements in mass spectrometry have also led to the development
[178] USFDA Guidance: Bioanalytical Method Validation for Biomarkers — USFDA Guidance: Bioanalytical Method Validation for Biomarkers USFDA Guidance: Bioanalytical Method Validation for Biomarkers On 21st January 2025, the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research issued final guidance "Bioanalytical Method Validation for Biomarkers" focusing on the importance of robust bioanalytical methods for evaluating biomarkers in drug development. The guidance aims to provide clarity on how to validate bioanalytical methods used to measure biomarkers in biological matrices like blood and urine. Unlike drug assays, biomarker assays often require a fit-for-purpose validation approach tailored to their intended use in regulatory decision-making or internal pharmaceutical development.
[180] M10 Bioanalytical Method Validation and Study Sample Analysis | FDA — M10 Bioanalytical Method Validation and Study Sample Analysis | FDA Skip to FDA Search FDA Guidance Documents About FDA In this section: Search for FDA Guidance Documents Search for FDA Guidance Documents Search for FDA Guidance Documents Search for FDA Guidance Documents The guidance describes recommendations for method validation for bioanalytical assays for nonclinical and clinical studies that generate data to support regulatory submissions, including the procedures and processes that should be characterized for chromatographic and ligand-binding assays that are used to measure the parent and active metabolites of drugs administered in nonclinical and clinical subjects. All written comments should be identified with this document's docket number: FDA-2019-D-1469. Search for FDA Guidance Documents Search for FDA Guidance Documents About FDA
[181] Trends and Challenges for Bioanalysis and Characterization of Small and ... — Structural, bioanalytical, characterization, and quality control studies are critical for successful drug development. These studies must be as accurate, sensitive, and selective as possible, and liquid chromatography coupled to tandem mass spectrometry (LC-MS-MS) has been the technique of choice for many areas of small molecule analysis for the past 30 years. During that time, rapid
[214] Ensuring Regulatory Compliance in Bioanalytical Method Development — Ensuring Regulatory Compliance in Bioanalytical Method Development Ensuring Regulatory Compliance in Bioanalytical Method Development This article explores the key aspects of ensuring regulatory compliance in bioanalytical method development, providing valuable insights for healthcare professionals and researchers in the field. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and the U.S. Food and Drug Administration (FDA) have established comprehensive guidelines for method validation in bioanalytical method development. Detailed documentation and record-keeping are fundamental to regulatory compliance in bioanalytical method development. In conclusion, ensuring regulatory compliance in bioanalytical method development requires a comprehensive approach that encompasses method validation, adherence to good practices, compliance with established guidelines, careful attention to technical details, and thorough documentation.
[215] PDF — For a long time, method validation procedures and strategies used in bioanalysis, as well as acceptance criteria needed for validation procedures, were a matter of personal prejudice. Many years there existed a lack of guidance uniformity on bioanalytical method development and validation within the bioanalytical commu-nity.
[216] Current Challenges for FDA-regulated Bioanalytical Laboratories for ... — and compliance issues related to bioanalytical ... series.) A high percentage of the recent FDA 483 observations issued to bioanalytical laboratories are related to method validation issues, as highlighted in the ... in the method validation report is incorrectly stated; data from Current Challenges for FDA-regulated Bioanalytical Laboratories
[247] Bioanalytical LC-MS/MS of protein-based biopharmaceuticals — The challenge of bioanalysis is to determine pharmaceutically active compounds at very low levels in highly complex biological matrices, such as plasma, serum, tissue, etc. In principle, all endogenous compounds can interfere with the LC-MS determination of the target therapeutic protein, and should therefore be removed as much as possible
[248] Matrix effects demystified: Strategies for resolving challenges in ... — This poses a challenge when analyzing complex biological matrices, as minor changes in mobile phase composition or gradient programs can also cause substantial coelution of matrix components and ion suppression. While HILIC is expected to have greater sensitivity in comparison to RPLC, several methods have reported higher LOQs with HILIC . As
[249] Analytical Chemistry in the 21st Century: Challenges, Solutions, and ... — When analyzing complex biological samples such as whole blood, plasma, urine, and biopsies, the sample preparation step is critical as it deals with complex matrices with moderate to high protein levels . Another element in the case of biological matrices is represented not only by inter-personal variability, but also by intra-personal variability.
[251] Recent Advances in Microfluidic Technology for Bioanalysis and ... — By implementing nanoliter-scale electro-membrane extraction inside a microfluidic device, model analytes from a 70 μL blood, plasma, or urine sample were extracted into an acceptor solution. ... A variety of other techniques was applied in microfluidic devices to sort and concentrate molecules or particles based on properties other than size
[252] Journal of Chromatography Open | Recent Advances in Bioanalysis ... — The special issue "Recent Advances in Bioanalysis", which will be published in the Journal of Chromatography Open, aims to showcase significant advancements in analysis of biomolecules. Specifically, it will focus on new separation technologies for biomolecule analysis, innovative biomolecule detection techniques, the use of process modelling for bioanalytical development, and advances in
[253] Recent Advances and Future Trends in Bioanalytical Chemistry — The trends in the field of bioanalytical have been driven by recent advances in emerging technologies such as microfabrication techniques, materials, and electronics, which facilitate the production of smaller, portable, and cheaper bioanalytical devices. The hot topics in bioanalytical science are summarized in Fig. 1.
[254] Recent advances in sample preparation techniques for quantitative ... — Herein, recent advances in sample preparation techniques for quantitative bioanalysis of pharmaceuticals in the past decade are reviewed and summarized, and the relative merits of each sample preparation technique are discussed. Besides, novel techniques such as electromembrane extraction and microfluidic devices are also addressed.
[255] New trends in bioanalysis sampling and pretreatment: How modern ... — This review explores the latest advancements in microsampling devices, including microfluidic and quantitative dried blood spot systems (mfDBS and qDBS, respectively), calibrated capillary-based devices, volumetric absorptive microsampling (VAMS) technologies, microneedle-based microsampling, radial-based DBS devices, membrane-based plasma separation technologies and vacuum-assisted blood collection systems. Modern innovations include volumetric absorptive microsampling (VAMS), advanced DBS platforms (e.g. based on microfluidics and capillary systems), membrane-based plasma separation and minimally invasive fluid capillary blood collection technologies, each tailored to specific applications and analytical needs. Other approaches dispense with a separated skin-prick moment and directly integrate microneedles into the device for better patient comfort, obtaining either fluid microsamples or dried blood samples on polymer (Tasso-M20).
[256] Advances in green sample preparation methods for bioanalytical ... — Article highlights. Introduction: This section highlights the importance of green sample preparation (GSP) and explores advancements in novel sorbent materials, greener solvents, and microextraction techniques, emphasizing their influence on modern bioanalysis.. Advanced sorbent materials for GSP methods in bioanalysis: This section provides advanced sorbent materials, including metal-organic
[258] Integrating of analytical techniques with enzyme-mimicking ... — Bioanalysis faces challenges in achieving fast, reliable, and point-of-care (POC) determination methods for timely diagnosis and prognosis of diseases. ... The integration of microfluidic chips with analytical techniques offers several benefits, such as easy miniaturization, need for low biological sample volume, etc., while also enhancing the
[259] Microfluidic platforms integrated with nano-sensors for point-of-care ... — Employing microfabrication techniques and microelectromechanical systems (MEMSs), arrays of nano-biosensors can be integrated into microfluidic devices, which serve as a versatile and more precise toolbox for monitoring the analytical performance of nano-biosensors in microscale environments . Thanks to the microfluidic integration, nano
[261] Unlocking the potential of bioanalytical data through machine learning — Recent advances in data-analysis techniques, including machine learning (ML), show promise to help overcome this limitation. ML can effectively extract latent beneficial information from complex bioanalytical data, thus facilitating the exploration of unknown relationships and patterns.
[262] Explainable AI for Bioinformatics: Methods, Tools and Applications — Artificial intelligence (AI) systems utilizing deep neural networks and machine learning (ML) algorithms are widely used for solving critical problems in bioinformatics, biomedical informatics and precision medicine. However, complex ML models that are often perceived as opaque and black-box methods …
[266] Strategies for automating analytical and bioanalytical laboratories - PMC — Here, the solid-phase extraction is of particular importance and is now one of the most frequently used sample preparation methods in bioanalysis . ... Artificial intelligence will increasingly find application in the automation of (bio)analytical processes. The main area of application here is initially data analysis.